Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CA 125 in gynecologic practice.

G D Malkasian, K C Podratz, C R Stanhope

    American Journal of Obstetrics and Gynecology
    |September 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.

    Gynecologic oncology·2013
    Same author

    Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.

    Gynecologic oncology·2013
    Same author

    Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer.

    Gynecologic oncology·2013
    Same author

    Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer.

    Gynecologic oncology·2012
    Same author

    Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study.

    Gynecologic oncology·2012
    Same author

    Referral and ascertainment bias in patients with synchronous and metachronous endometrial malignancy.

    European journal of gynaecological oncology·2010

    Serum CA 125 levels can indicate recurrence in ovarian cancer patients. Elevated CA 125 levels were detected 2-5 months before clinical recurrence in ovarian cancer patients, suggesting its utility in monitoring disease.

    Area of Science:

    • Gynecology
    • Oncology
    • Clinical Chemistry

    Background:

    • The tumor marker CA 125 is often used in monitoring ovarian cancer.
    • Its utility in early detection of recurrence requires further investigation.

    Purpose of the Study:

    • To evaluate the role of serum CA 125 levels in women with benign ovarian lesions, uterine fundal lesions, and ovarian cancer recurrence.

    Main Methods:

    • Serum CA 125 levels were measured in women with benign ovarian lesions, uterine fundal lesions, and ovarian cancer patients with prior negative second-look laparotomy.
    • Serial CA 125 levels were analyzed in patients who later experienced recurrence.

    Main Results:

    • Elevated CA 125 levels (>35 U/ml) were observed in some patients with endometriosis and endometrial carcinoma.

    Related Experiment Videos

  • In ovarian cancer patients with recurrence, elevated CA 125 levels were detected 2-5 months prior to clinically apparent disease.

    • Conclusions:

    • Serial monitoring of serum CA 125 may aid in the early detection of recurrent epithelial ovarian carcinoma.
    • CA 125 levels in benign conditions and endometrial carcinoma showed variable results.